This page shows the latest radioligand therapy news and features for those working in and with pharma, biotech and healthcare.
The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients.
Novartis has revealed new data from a phase 3 trial evaluating its targeted radioligand therapy (RLT) in late stage advanced prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) ... This] data from the first phase 3 study of a
We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. ... compared the radioligand therapy plus best standard of care (SoC) to SoC alone.
Novartis’ investigational radioligand therapy 177Lu-PSMA-617 hit both primary endpoints in a phase 3 trial in patients with advanced prostate cancer. ... the radioligand therapy plus best standard of care (SoC) to SoC alone.
Next-generation treatment is more effective than current therapy. Novartis has data from a phase 2 study of its next-generation monoclonal antibody ligelizumab (QGE031), demonstrating superior efficacy compared to its ... Among the other promising
Lu-PSMA-617, a radioligand therapy for prostate cancer which has phase 3 readouts due in the near future. ... It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...